Jeena Sikho Lifecare Reports Strong Growth and Dividend Payout

Revenue: ₹801.36 crore (FY26) vs ₹469.07 crore (FY25)
Net Profit: ₹221.70 crore (FY26) vs ₹79.94 crore (FY25)

Reader Takeaway: Strong operational scaling and profit growth drive dividend payout; watch for board restructuring outcomes at AGM.

What just happened

Jeena Sikho Lifecare Limited has released its annual results and confirmed its 9th Annual General Meeting (AGM) for September 28, 2026. The company reported a significant jump in financial performance for the year ending March 31, 2026, and recommended a final dividend of ₹4.50 per equity share of ₹2 face value. September 21, 2026, is set as the record date for dividend eligibility.

Why this matters

The leap in net profit to ₹221.70 crore from ₹79.94 crore reflects aggressive expansion, including the addition of 561 hospital beds. With 2,300 beds now operational across 119 centers in 23 states, the company is capitalizing on a 65% increase in in-patient admissions and a 69% rise in out-patient consultations. This growth momentum is being supported by proposed significant financial headroom for inter-corporate loans and investments.

Board and Management Update

The company is proposing a major restructuring of its board, including the reappointment of Managing Director Mr. Manish Grover and several Whole-time Directors. New appointments include Mr. Ajay Sharma, Mrs. Sapna Singh, Dr. Ish Sharma, and Mr. Ankush Kaushal, signaling a shift to accommodate a larger institutional footprint.

Special Business Proposals

Shareholders will vote on special resolutions to authorize:

• Granting of loans, guarantees, and security to related parties up to ₹100 crore under Section 185.
• Investments and loans under Section 186 up to an aggregate of ₹700 crore.

Risks to watch

Management has highlighted risks related to regulatory compliance, reputational management, and third-party dependencies as critical factors as the company continues to scale its healthcare delivery network across India.

What to track next

Investors should monitor the outcome of the shareholder vote on Section 185 and 186 approvals, which will dictate the company's capital allocation flexibility for the coming fiscal year.